Aerska, a fresh-faced biotech company, raised $21 million (€18 million) in seed funding in October, in evidence of both the opportunity and challenge ahead of the company. The company founded by Jack O’Meara and David Hardwicke is developing RNA-based therapies for dementia patients. For many start-ups in the biotech sphere, large tranches of early-stage capital are a must, just to get to the first set of trials. For O’Meara and Hardwicke, it’s the next stage of their careers, having both done it before. O’Meara co-founded Ochre Bio, an RNA medicines company focused on liver disease, while Hardwicke held roles at…

Want to continue reading?

Unlock this article – and everything else on The Currency – with an annual membership and receive a free TUMI Alpha Bravo backpack delivered to your door.

Subscribe

Cancel at any time.

Are you already a member? .